Brief: Crescita Therapeutics Announces 9-Country Licensing Agreement With Croma Pharma For Pliaglis
28/06/2021 12:59
June 28 (Reuters) - Crescita Therapeutics Inc CTX.TO :
* CRESCITA THERAPEUTICS ANNOUNCES 9-COUNTRY LICENSING
AGREEMENT
WITH CROMA PHARMA FOR PLIAGLIS®
* CRESCITA THERAPEUTICS - CO ELIGIBLE TO RECEIVE COMBINATION
OF
UPFRONT, CUMULATIVE SALES & OTHER MILESTONE PAYMENTS THAT COULD
REACH EUR 1.25 MILLION
* CRESCITA THERAPEUTICS INC - CRESCITA WILL BE SOLE SUPPLIER
OF
PLIAGLIS UNDER AGREEMENT AT A PRICE PER UNIT INCLUDING A PROFIT
MARGIN
Source text for Eikon: ID:nBw1SCzx8a
Further company coverage: CTX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium